The seamless transition of a patient’s medical history from a specialized clinic to a regional emergency department has historically been throttled not by technology, but by deliberate corporate strategy. This phenomenon, known as health information blocking, represents a critical friction point in the United States healthcare system that the 21st Century Cures Act of 2016 was specifically designed to eliminate. Legal definitions classify information blocking as any practice by a health IT developer, health information exchange, or healthcare provider that is likely to interfere with or discourage the access, exchange, or use of electronic health information. As of 2026, the landscape has shifted from a systemic culture of data hoarding toward a more fragmented reality where progress for the many is slowed by the resistance of a few.
Foundations of Health Information Blocking and Key Industry Players
The 21st Century Cures Act of 2016 served as the legislative cornerstone for modern interoperability, but its practical implementation required years of regulatory refinement. The ecosystem involves a diverse array of participants, including certified health IT developers, expansive hospital networks, and regional Health Information Exchange (HIE) organizations. These entities are responsible for the digital plumbing of the medical world, yet their incentives do not always align with the goal of total data liquidity. To ensure compliance, the Office of the National Coordinator for Health Information Technology (ONC) and the HHS Office of Inspector General (OIG) maintain rigorous monitoring of data exchange practices across the country.
The fundamental purpose of federal intervention is to ensure that patient data remains liquid, moving effortlessly between different platforms and providers without technical or financial interference. Between 2021 and 2025, regulatory frameworks focused on establishing the “ground rules” for what constitutes an acceptable reason to withhold data. From 2026 to 2028, the industry focus is shifting from general education toward a zero-tolerance policy for those who continue to obstruct the flow of information. This oversight is vital for a healthcare system that increasingly relies on real-time data to make life-saving clinical decisions.
Comparative Dimensions: Data Interference Trends (2019–2025)
Prevalence and Industry Penetration
There is a stark contrast between the perceived “widespread” nature of information blocking and the actual statistical occurrence observed over the last several years. In 2019, an overwhelming 90% of HIE organizations reported that they regularly encountered some form of data interference. However, by 2025, this figure had dropped significantly to 71%, indicating that the majority of the market is slowly moving toward a more transparent operational model. This suggests that the threat of federal penalties has successfully pressured many organizations to abandon their more aggressive data-hoarding tactics in favor of regulatory compliance.
Furthermore, the perception of how pervasive this problem is among technology providers has undergone a dramatic transformation. In 2019, approximately 55% of HIEs believed that “most or all” health IT developers were actively engaging in blocking practices. By 2025, that number plummeted to just 27%, signaling that the industry no longer views data interference as a standard culture within the software market. While the problem has not been entirely eradicated, the shift toward a more open market is evident as the industry moves away from a systemic culture of secrecy.
Operational Consistency and Repeat Behavior
While the widespread nature of blocking has diminished, a more stubborn problem has emerged in the form of “routine” behavior. Data indicates that approximately one-third of HIEs continue to experience frequent and consistent data interference from a concentrated group of health IT developers. This “bad actor” phenomenon suggests that while the broader market is improving, a small minority of organizations has integrated information blocking into their standard operating procedures. This group remains unmoved by general industry trends and continues to prioritize proprietary control over patient data mobility.
The situation is similarly stagnant within the provider space, where one-fifth of HIEs still report that hospitals and health systems routinely interfere with data exchange. Unlike the broader industry, which shows a clear trajectory toward openness, these repeat offenders maintain a level of consistency that suggests deliberate obstruction. This distinction between a generally compliant market and a core group of routine blockers is the primary challenge facing regulators today. It requires a move away from broad industry warnings toward more surgical interventions.
Mechanisms of Obstruction and Financial Barriers
The tactics used to interfere with data flow have evolved, with financial barriers remaining the most prevalent tool for obstruction. In 2019, approximately 80% of HIEs reported that IT developers used excessive fees and complex pricing structures to make data exchange prohibitively expensive. Although this number decreased to 60% by 2025, fees remain a primary method of technical interference. These “toll booths” on the digital highway allow entities to claim they are sharing data while making the process so costly that it becomes functionally impossible for smaller organizations to participate.
Beyond financial hurdles, outright refusals to share data continue to impact the medical landscape. Approximately one-third of HIEs report that both IT companies and large health systems still occasionally refuse to move data, citing various technical or administrative excuses. While these refusals are less common than price-based blocking, they represent a more direct defiance of federal mandates. The persistent use of these methods highlights the fact that technical capabilities are rarely the limiting factor; instead, the barriers are almost entirely administrative and strategic in nature.
Structural Obstacles and Regulatory Enforcement Challenges
One of the primary difficulties in achieving total interoperability has been the multi-year delay between the passage of the 21st Century Cures Act and the finalization of practical penalties. Dr. Thomas Keane, the National Coordinator for Health Information Technology, previously noted that as of early 2024, the federal government had not yet levied formal penalties against many known offenders. This lack of immediate financial consequence allowed routine blockers to persist in their behavior without fear of significant repercussions. The “last mile” of interoperability has proven to be the most difficult to secure, as education alone has not been enough to sway the most entrenched actors.
Moving from “notices of nonconformity” to aggressive enforcement actions like decertification and OIG fines involves significant technical and administrative complexity. Regulators must be able to distinguish between legitimate technical failures and intentional blocking, a task that requires deep forensic analysis of health IT systems. However, the current administration has signaled a clear commitment to overcoming these hurdles. The transition toward actual litigation and the imposition of heavy fines is seen as the only way to finally dismantle the remaining silos maintained by the industry’s most persistent repeat offenders.
Strategic Synthesis: Recommendations for Interoperability
The transition from widespread, industry-wide blocking to a concentrated group of routine offenders necessitated a fundamental shift in federal strategy. Regulators recognized that broad educational campaigns had reached their limit of effectiveness, as the remaining blockers were not acting out of ignorance but out of a calculated business interest. By 2026, the focus moved toward targeted litigation and the imposition of significant financial penalties for those who maintained data interference as a standard operating procedure. This shift provided the necessary deterrent to discourage the use of predatory pricing and technical fees as a means of obstruction.
The prioritization of enforcement against specific methods, such as discriminatory pricing and outright data refusals, was instrumental in maximizing national data liquidity. Authorities finally moved beyond simple notices of nonconformity and began the process of decertifying non-compliant products, which stripped bad actors of their market legitimacy. These actions ensured that the goals of the 21st Century Cures Act were realized, allowing patient information to follow the individual across any provider or platform. Ultimately, the industry learned that the cost of non-compliance would finally exceed the perceived benefits of data hoarding.
